MedTrace Logo

Yueju Pill Combined With Standard Therapy In Advanced Biliary Tract Cancer

NCT07169916 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2025-09-12

No results posted yet for this study

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the impact of Yueju Pill on quality of life and treatment efficacy in patients with advanced biliary tract cancer (BTC) receiving standard therapy.

Conditions

  • Biliary Tract Cancer (BTC)

Interventions

DRUG

Yueju Pill + Standard Anti-tumor Therapy

Group A (Intervention): Standard therapy + Yueju Pill (6-9 g per dose, twice daily, orally until disease progression or intolerable toxicity).

DRUG

Placebo + Standard anti-tumor therapy

Group B (Control): Standard therapy + placebo (identical in appearance, packaging, dosage, and administration frequency to Yueju Pill).

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    collaborator OTHER

  • Shanghai Geriatric Medical Center

    collaborator OTHER

  • Minhang Central Hospital

    collaborator UNKNOWN

  • Xuhui Central Hospital, Shanghai

    collaborator OTHER

  • Fudan University

    lead OTHER

Principal Investigators

  • Jia Fan, Professor · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07169916 on ClinicalTrials.gov